K
Kevin L. Winthrop
Researcher at Oregon Health & Science University
Publications - 430
Citations - 30758
Kevin L. Winthrop is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 68, co-authored 362 publications receiving 24354 citations. Previous affiliations of Kevin L. Winthrop include University of Alabama at Birmingham & Duke University.
Papers
More filters
Journal ArticleDOI
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
David E. Griffith,Timothy R. Aksamit,Barbara A. Brown-Elliott,Antonino Catanzaro,Charles L. Daley,Fred M. Gordin,Steven M. Holland,Robert Horsburgh,Gwen A. Huitt,Michael F. Iademarco,Michael D. Iseman,Kenneth N. Olivier,Stephen J. Ruoss,C. Fordham von Reyn,Richard J. Wallace,Kevin L. Winthrop +15 more
TL;DR: Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease Key Laboratory Features of N TM Health Careand Hygiene-associated Disease Prevention Prophylaxis and Treatment of NTM Disease Introduction Methods.
Journal ArticleDOI
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TL;DR: These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Journal ArticleDOI
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Daniel E. Furst,E.C. Keystone,J. Braun,F. C. Breedveld,G.-R. Burmester,F De Benedetti,Thomas Dörner,Paul Emery,Roy Fleischmann,Allan Gibofsky,Joachim R. Kalden,A. Kavanaugh,Bruce Kirkham,Philip J. Mease,J. Sieper,Nora G. Singer,Josef S Smolen,P.L.C.M. van Riel,Michael H. Weisman,Kevin L. Winthrop +19 more
TL;DR: The consensus statement is annotated to document the credibility of the data supporting it as much as possible and the number of possible references has become so large that reviews are sometimes included; if they contain category A references, they will be referred to as category A evidence.
Journal ArticleDOI
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Maxime Dougados,Martin Soubrier,Anna Antunez,Peter V. Balint,Alejandro Balsa,Maya H Buch,Maya H Buch,Gustavo Casado,Jacqueline Detert,Bassel Elzorkany,Paul Emery,Paul Emery,Najia Hajjaj-Hassouni,Masayoshi Harigai,Shue Fen Luo,Reka Kurucz,Gabriel Maciel,Emilio Martin Mola,Carlomaurizio Montecucco,Iain B. McInnes,Helga Radner,Josef S Smolen,Yeong Wook Song,Harald E. Vonkeman,Kevin L. Winthrop,Jonathan Kay +25 more
TL;DR: In this multinational sample of rheumatoid arthritis patients, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities.
Journal ArticleDOI
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro,Cécile Gaujoux-Viala,Jackie L Nam,Jackie L Nam,Josef S Smolen,Maya H Buch,Maya H Buch,Laure Gossec,Désirée van der Heijde,Kevin L. Winthrop,Robert Landewé +10 more
TL;DR: The findings from this SLR confirm the known safety pattern of s DMARDs and bDMARDs for the treatment of RA.